Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* One of the following diagnoses:~  * Pathologically confirmed acute myeloid leukemia (AML) meeting one of the following criteria:~    * Newly diagnosed AML, over age 60, and not eligible for higher priority protocols~   * Newly diagnosed AML and unable to receive anthracycline-containing or high-dose cytarabine-containing regimens~   * AML in relapse~   * AML refractory to two courses of standard induction chemotherapy or one course of high-dose cytarabine-containing induction chemotherapy~ * Chronic myelogenous leukemia in accelerated phase or myeloid blast crisis~ * Refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocytic leukemia~* More than 25% of bone marrow blasts must be CD33 positive~* Not a candidate for immediate bone marrow transplantation with a HLA-compatible donor~* No active CNS leukemia~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Karnofsky 60-100%~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin no greater than 2 mg/dL (unless due to leukemia or Gilbert's disease)~* Alkaline phosphatase no greater than 2.5 times upper limit of normal (ULN)~* AST no greater than 2.5 times ULN~Renal:~* Creatinine less than 2 mg/dL OR~* Creatinine clearance greater than 60 mL/min~Cardiovascular:~* No New York Heart Association class III or IV cardiac disease~Pulmonary:~* No pulmonary disease~Other:~* No detectable antibodies to monoclonal antibody M195~* No serious active uncontrolled infection~* No other concurrent active malignancy requiring therapy~* No other serious or life-threatening conditions that would preclude study~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 3 weeks since prior biologic therapy and recovered~Chemotherapy:~* See Disease Characteristics~* Prior hydroxyurea allowed if discontinued before study treatment~* At least 3 weeks since other prior chemotherapy and recovered~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 3 weeks since prior radiotherapy and recovered~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- bismuth Bi 213 monoclonal antibody M195 & cytarabine (Type: EXPERIMENTAL): Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD.~Patients are followed twice weekly for 4 weeks and then monthly for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).